Global ACE Inhibitors Market Size, Trends, and Forecast 2033: Latest Insights and Key Opportunities

The ace inhibitors market size has grown steadily in recent years. It will grow from $6.9 billion in 2023 to $7.24 billion in 2024 at a compound annual growth rate (CAGR) of 4.9%. The growth in the historic period can be attributed to risen cardiovascular disease incidence, increased aging population, clinical effectiveness and safety profile, prevalence of diabetes, regulatory endorsement and guidelines.

The ace inhibitors market size is expected to see strong growth in the next few years. It will grow to $9 billion in 2028 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be attributed to growing global burden of cardiovascular diseases, expanding hypertension treatment guidelines, advancements in combination therapies, focus on heart failure management, rising awareness and healthcare access. Major trends in the forecast period include focus on kidney protection, preference for renin-angiotensin system inhibitors, generic competition and pricing pressures, patient-centric approaches in healthcare, regulatory updates and safety considerations.

Market Overview -
ACE inhibitors, also known as angiotensin-converting enzyme (ACE) inhibitors, refer to a type of medication used to treat and manage hypertension. They function by stopping the body's enzyme from generating angiotensin II, a chemical that constricts blood vessels and raises blood pressure. Its basic function is to relax the veins and arteries to reduce blood pressure.

Download Free Sample of Report -

https://www.thebusinessresearchcompany.com/sample.aspx?id=10671&type=smp

Rising Hypertension Rates Fuel The Growth Of Ace Inhibitors Market
The increasing prevalence of hypertension disorders is expected to drive the growth of the ACE inhibitors market going forward. High blood pressure, medically known as hypertension, is a condition characterized by elevated pressure within the blood vessels. ACE inhibitors, also known as angiotensin-converting enzyme inhibitors, are a group of medications utilized to treat and control hypertension. These medications function by relaxing the blood vessels, resulting in a reduction in blood pressure and an improvement in blood flow. For instance, in March 2023, according to the World Health Organization, a Switzerland-based specialized agency of the United Nations, approximately 1.28 billion adults between the ages of 30 and 79 were affected by hypertension worldwide, with a majority (two-thirds) residing in low- and middle-income nations. In the past 30 years, there has been an increase of 650 million people aged 30-79 who have hypertension. An estimated 46% of adults with hypertension are unaware of their condition, lacking a diagnosis. Over the last 30 years, the number of adults aged 30-79 who have hypertension has increased by 650 million. An estimated 46% of persons with hypertension are unaware of their condition since they are not diagnosed. Therefore, the increasing prevalence of hypertension disorders is driving the growth of the ACE inhibitors market.

Competitive Landscape -
Major companies operating in the ace inhibitors market report are Pfizer Inc.,Novartis AG,Johnson & Johnson Private Limited, Merck KGaA,Sanofi S.A.,Bayer AG,United Theutics Corporation,Teva Pharmaceutical Industries Ltd.,Bristol-Myers Squibb Co.,Takeda Pharmaceuticals Company,Daiichi Sankyo Company Ltd.,UCB Schwarz Pharma Inc.,Solvay Pharmaceuticals B.V.,Endo International plc,Otto Brandes GmbH,Sun Pharmaceutical Industries Ltd.,Boehringer Ingelheim,Bausch Health Companies Inc.,Dr. Reddy's Laboratories,Abbott Laboratories,Eli Lilly and Company,Cipla Limited, GlaxoSmithKline plc,Cadila Healthcare Limited,AbbVie Inc., Mylan N.V., Sandoz Group AG,Accord Healthcare Ltd.,AstraZeneca plc,Lupin Limited,Macleods Pharmaceuticals Limited,Zydus lifescience Ltd.,Apotex Inc.

Product Innovations Drive Growth In Ace Inhibitors Market
Product innovations are a key trend gaining popularity in the ACE inhibitors market. Major companies operating in the ACE inhibitors market are focused on developing innovative products to strengthen their position and gain a competitive advantage. For instance, in February 2023, Travere Theutics, a US-based biopharmaceutical company, announced FDA approval of FILSPARI™ (sparsentan), a first-of-its-kind non-immunosuppressive therapy for use in patients with IgA nephropathy (IgAN). These treatments include systemic glucocorticoids, angiotensin-converting enzyme (ACE) inhibitors, and antihypertensive medications, including angiotensin-receptor blockers (ARBs). It is the only non-immunosuppressive therapy approved and a once-daily oral medicine designed to treat adults with primary IgAN at risk of rapid disease development and who typically have a UPCR of less than 1.5 g/g and proteinuria.

Browse Full Report @

https://www.thebusinessresearchcompany.com/report/ace-inhibitors-global-market-report

Key Segments -

The ace inhibitors market covered in this report is segmented -

1) By Type: Sulfhydryl-containing Agents, Dicarboxylate-containing Agents, Phosphonate-containing Agents
2) By Drug: Ramipril, Enalapril, Benazepril, Fosinopril, Captopril, Moexipril, Other Drugs
3) By Dosage Form: Oral Tablets, Oral Solutions
4) By Application: Heart Failure, Chronic Kidney Disease, Hypertension, Diabetes, Heart Attack, Other Applications
5) By End-Users: Hospitals, Online Drug Stores, Other End-Users

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Want To Know More About The Business Research Company?

The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database

The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.